---
title: "Alterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300098655.md"
description: "Alterity Therapeutics (AU:ATH) has scheduled its 2026 Annual General Meeting for November 20, 2026, and set October 2, 2026, as the deadline for director nominations. These governance milestones are critical for shareholder engagement and board composition. The company, a biopharmaceutical firm listed on ASX and Nasdaq, currently holds a 'Buy' rating with an A$0.95 price target."
datetime: "2026-09-25T03:57:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300098655.md)
  - [en](https://longbridge.com/en/news/300098655.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300098655.md)
generator: "portal-rs"
---

# Alterity Therapeutics Sets 2026 AGM Date and Director Nomination Deadline

An announcement from Alterity Therapeutics ( (AU:ATH) ) is now available.

Alterity Therapeutics has scheduled its next Annual General Meeting for 11:00 a.m. AEDT on 20 November 2026, with full meeting details to be circulated to shareholders in a forthcoming Notice of Meeting and posted on the ASX announcements platform and the company’s website. The company has also set 2 October 2026 as the closing date for written director nomination submissions, underscoring upcoming governance decisions that may influence board composition and strategic direction.

These corporate calendar milestones mark an important point for shareholder engagement as Alterity advances its biopharmaceutical programs, providing investors a formal forum to scrutinize management and future plans. The AGM and director nomination window may shape leadership oversight at a time when regulatory compliance and transparent governance are increasingly critical in the life sciences industry.

The most recent analyst rating on (AU:ATH) stock is a Buy  
 with a A$0.95 price target.  
 To see the full list of analyst forecasts on Alterity Therapeutics stock,  
 see the AU:ATH Stock Forecast page. 

**More about Alterity Therapeutics**

Alterity Therapeutics Limited is a biopharmaceutical company listed on the ASX and Nasdaq, focused on developing novel therapies for neurodegenerative conditions. The Melbourne-based firm targets global markets for innovative treatments, positioning itself within the neuroscience and specialty drug development sector.

**YTD Price Performance:** -14.00%

**Average Trading Volume:** 263,664

**Technical Sentiment Signal:** Sell

**Current Market Cap:** A$96.24M

Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [ATHE.US](https://longbridge.com/en/quote/ATHE.US.md)
- [ATH.AU](https://longbridge.com/en/quote/ATH.AU.md)

## Related News & Research

- [Alterity Therapeutics Seeks Quotation for New ASX Shares](https://longbridge.com/en/news/299120002.md)
- [Alterity Therapeutics issues 8,400,000 shares tied to exercised options at A$ 0.5 each](https://longbridge.com/en/news/298298137.md)
- [Insider Move at Biotech Firm Sparks Fresh Investor Interest](https://longbridge.com/en/news/298398581.md)
- [Alterity Therapeutics Issues 8.4 Million Shares Under Underwriting Deal](https://longbridge.com/en/news/298249430.md)
- [Alterity Therapeutics issues shares from exercise of listed options at A$0.5 each](https://longbridge.com/en/news/297504784.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**